Evidence map›Paper›PMID 35360008›Full record

ArticleFrontiers in cardiovascular medicine2022

RNA Virus Gene Signatures Detected in Patients With Cardiomyopathy After Chemotherapy; A Pilot Study.

Kyle Varkoly, Shaoyuan Tan, Roxana Beladi, David Fonseca, Isabela Rivabem Zanetti, Simona Kraberger, Chintan Shah, Jordan R Yaron, Liqiang Zhang, Michael Juby and 9 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 6 institutions in 1 country.

Kyle VarkolyDepartment of Internal Medicine, McLaren Macomb Hospital- Michigan State University College of Human Medicine, Mt Clemens, MI, United States.
Shaoyuan TanDepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, United States.
Roxana BeladiCenter for Personalized Diagnostics, The Biodesign Institute, Arizona State University, Tempe, AZ, United States.
David FonsecaCenter for Personalized Diagnostics, The Biodesign Institute, Arizona State University, Tempe, AZ, United States.
Isabela Rivabem ZanettiCenter for Personalized Diagnostics, The Biodesign Institute, Arizona State University, Tempe, AZ, United States.
Simona KrabergerThe Biodesign Center of Fundamental and Applied Microbiomics, Center for Evolution and Medicine, School of Life Sciences, Arizona State University, Tempe, AZ, United States.
Chintan ShahDivision of Hematology/Oncology, Department of Medicine, University of Florida, Gainesville, FL, United States.
Jordan R YaronCenter for Personalized Diagnostics, The Biodesign Institute, Arizona State University, Tempe, AZ, United States.
Liqiang ZhangCenter for Personalized Diagnostics, The Biodesign Institute, Arizona State University, Tempe, AZ, United States.
Michael JubyCenter for Personalized Diagnostics, The Biodesign Institute, Arizona State University, Tempe, AZ, United States.
Ayman FathDepartment of Internal Medicine, Dignity Health, Creighton University, Phoenix, AZ, United States.
Sriram AmbadapadiCenter for Personalized Diagnostics, The Biodesign Institute, Arizona State University, Tempe, AZ, United States.
Melanie HouseDepartment of Internal Medicine, Dignity Health, Creighton University, Phoenix, AZ, United States.
Paul MaranianCenter for Personalized Diagnostics, The Biodesign Institute, Arizona State University, Tempe, AZ, United States.
Carl J PepineDivision of Cardiology, Department of Medicine, University of Florida, Gainesville, FL, United States.
Arvind VarsaniThe Biodesign Center of Fundamental and Applied Microbiomics, Center for Evolution and Medicine, School of Life Sciences, Arizona State University, Tempe, AZ, United States.
Jan MorebHematologic Malignancies, Transplantation and Cellular Therapy Program, Forsyth Medical Center, Derrick L Davis Cancer Center, Winston-Salem, NC, United States.
Stacey Schultz-CherryDepartment of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, TN, United States.
Alexandra R LucasCenter for Personalized Diagnostics, The Biodesign Institute, Arizona State University, Tempe, AZ, United States.
Arizona State University · USUniversity of Florida · USCreighton University · USSt. Jude Children's Research Hospital · USMcLaren Macomb · USNovant Health Forsyth Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Viral infections are pervasive and leading causes of myocarditis. Immune-suppression after chemotherapy increases opportunistic infections, but the incidence of virus-induced myocarditis is unknown. Objective: An unbiased, blinded screening for RNA viruses was performed after chemotherapy with correlation to cardiac function. Methods: High-throughput sequencing of RNA isolated from blood samples was analyzed following chemotherapy for hematological malignancies ( Results: On initial rigorous analysis, low levels of influenza orthomyxovirus and avian paramyxovirus sequences were detectable, but without significant correlation to LVEF (r = 0.208). A secondary broad data mining analysis for virus sequences, without filtering human sequences, detected significant correlations for paramyxovirus with LVEF after chemotherapy (r = 0.592, Conclusions: This is the first report of RNA virus screening in circulating blood and association with changes in cardiac function among patients post chemotherapy, using unbiased, blinded, high-throughput sequencing. Influenza orthomyxovirus, avian paramyxovirus and retrovirus sequences were detectable in patients with reduced LVEF. Further analysis for RNA virus infections in patients with cardiomyopathy after chemotherapy is warranted.

Indexed as

cancercardiomyopathychemotherapyimmune suppressioninfectionLVEFRNAvirus

Identifiers

PMID35360008
PMCPMC8962958
OpenAlexW4220779180

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.